AI assistant
Sending…
Keros Therapeutics, Inc. — Director's Dealing 2021
Jun 26, 2021
32602_dirs_2021-06-25_026f0614-6eef-425e-a26d-20e5db67b920.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2021-06-24
Reporting Person: Lachey Jennifer (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-24 | Common Stock | M | 6500 | $0.30 | Acquired | 84407 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-24 | Employee Stock Option (right to buy) | $0.30 | M | 6500 | Disposed | 2028-03-25 | Common Stock (6500) | Direct |
Footnotes
F1: Immediately exercisable.
More from Keros Therapeutics, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 3
Regulatory Filings
2026
Jun 1
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 22
Investor Presentation
2026
Mar 4
Annual Report
2026
Mar 4
Regulatory Filings
2026
Mar 4
Director's Dealing
2026
Feb 26